Revive Therapeutics Ltd.

CSE:RVV Canada Healthcare — Drug Manufacturers - Specialty & Generic

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying an…

revivethera.com

Click to toggle · Cmd+Click for exclusive

Transactions 2026-08-19 Financing

Open PDF

Revive Therapeutics Announces Proposed Shares for Debt Settlement

News release - English.pdf

News 2026-08-19

Open PDF

Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio

News release - English.pdf

News 2026-08-12

Open PDF

Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study

News release - English.pdf

Transactions 2026-07-17 Financing

Report of exempt distribution (45-106F1).pdf

News 2026-07-15

Open PDF

News release - English.pdf

Transactions 2026-06-26 Financing

Open PDF

Revive Therapeutics Announces Proposed Private Placement

News release - English.pdf

Results 2026-06-02

Open PDF

Interim MD&A - English.pdf

Results 2026-06-02

Open PDF

Interim financial statements/report – English.pdf

News 2026-05-20

Open PDF

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

News release - English.pdf

News 2026-03-11

Open PDF

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

News release - English.pdf

Results 2026-02-28 Financials

Open PDF

Interim MD&A - English.pdf

Results 2026-02-27 Financials

Open PDF

Interim financial statements/report – English.pdf

News 2025-12-15

Open PDF

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

News release - English.pdf

Results 2025-11-28 Financials